



GEDEON RICHTER

Health is our mission

Celebrating **125** years

2025

# Table of Contents

This brochure is published by Gedeon Richter Plc.  
Issued under the supervision of the Global PR, CSR and  
Government Relations Department.

Photography: Richter Photo Archive; Shutterstock

Editorial close: 2026.02.02. PR/293/2026

Foreword	<b>02</b>
Board of Directors of Gedeon Richter Plc, a Global Pharmaceutical Company	<b>04</b>
Our Mission	<b>06</b>
Richter Group – Company Overview and Key Figures	<b>07</b>
Business Units	<b>18</b>
Richter Strategy 2035	<b>23</b>
Key Events of the Year	<b>26</b>

# Chairman's Foreword



**E. Sylvester Vizi**  
Chairman

Gedeon Richter Plc is one of Central Europe's most successful corporate groups and continues to operate with Hungarian ownership and management. Our products reach nearly one hundred markets worldwide, while more than 90% of our revenues are generated from international sales. We have a long-standing commitment to research and development: approximately 10% of our annual revenues are reinvested in R&D. The intellectual added value of our most successful medicines is Hungarian, so the profit they generate also enriches our country.

We collaborate with a major American company, AbbVie, in central nervous system research. Through acquisitions, we have also become a key European player in women's healthcare. Our international standing is further demonstrated by the fact that the President of the European Commission invited Gábor Orbán to join a leadership group addressing Europe's pharmaceutical challenges, and he also participated in the delegation that held talks at the White House in Washington in autumn 2025.

A major milestone in our biotechnology business is the FDA approval of our denosumab biosimilar development, confirming that we remain at the forefront of one of the fastest-growing segments of the global pharmaceutical industry.

In 2025 we also received numerous recognitions: Richter ranked second among the most actively traded issuers at the Budapest Stock Exchange; Figyelő ranked us the Most Innovative Company of the Year; and the Richter Centre was awarded "Headquarters of the Year". I had received the Jedlik Ányos Award in recognition of my inventive and intellectual property activities, while our CEO received five prestigious awards, including the Officer's Cross of the Hungarian Order of Merit.

These achievements confirm that Richter remains a stable, innovative and leading player in the international pharmaceutical industry.

# CEO's Foreword

Building on Richter's 125-year heritage, we now operate as a global company that successfully combines scientific excellence, the ability to adapt to a rapidly changing industry environment, and the strength of Hungarian intellectual capital.

We are particularly proud that all this is achieved from our Hungarian headquarters, relying on the dedication of nearly twelve thousand colleagues, while our products reach almost one hundred countries and provide safe and innovative therapeutic solutions to millions of patients worldwide.

In recent years we have established the operational foundations and capabilities that enable us to build a strong, long-term presence across several key therapeutic areas. Our new strategy extending to 2035 defines the directions along which we will further strengthen our innovation performance, while ensuring improved access to essential medicines remains a priority.

We believe that scientific progress and corporate social responsibility reinforce one another, enabling us to expand our therapeutic portfolio and maintain our international competitiveness in the decade ahead.

Our financial and operational objectives balance stable growth with long-term sustainability. We continue to strengthen our R&D capacities and remain open to external collaborations that create new opportunities and contribute to our value-creating operations.

Richter's strength lies in professional excellence, cooperation and its capability for continuous renewal. Guided by these principles, we moved forward in 2025 and will continue to create value for patients, employees and shareholders worldwide in the years and decades to come.



**Gábor Orbán**  
Chief Executive Officer



# Board of Directors of Gedeon Richter Plc, a Global Pharmaceutical Company



**Prof. Dr E. Sylvester Vizi**  
**Chairman of the Board of Directors**

Physician, pharmacologist,  
university professor;  
Professor Emeritus;  
Former President of the Hungarian  
Academy of Sciences



**Gábor Orbán**  
**Chief Executive Officer**

Economist; former State Secretary at  
the Ministry for National Economy;  
Chairman of the SE NEO Foundation



**Dr Ilona Hardy Pintérné**  
**Deputy Chair of the Board of Directors**  
Lawyer and capital markets professional;  
Founding Chair of the Aranykor Voluntary  
Pension Fund;

First Chief Executive Officer  
of the Budapest Stock Exchange



**Erik Bogsch**  
**Lifetime Honorary Chairman**  
Chemical engineer and economist




**László András Kovács**  
**Chief Financial Officer**

Economist with expertise in finance,  
auditing and logistics



**Gabriella Balogh**  
**Member of the Board of Directors**

Chemical engineer and marketing economist;  
former Director of Marketing  
and Sales at OTP Bank;  
Board Member and co-owner of Net Media Zrt.



**Dr Péter Cserhádi**  
**Member of the Board of Directors**

Physician; former Government  
Commissioner;  
Director of the National Institute of  
Medical Rehabilitation



**Prof. Dr Nándor Pál Ács**  
**Member of the Board of Directors**

Obstetrician and gynaecologist, surgeon, clinical  
pharmacologist, health economist;  
Director of the Department of Obstetrics and  
Gynaecology at Semmelweis University



**Mrs Lászlóné Németh**  
**Member of the Board of Directors**

Politician and economic expert; former  
Minister for National Development;  
former Deputy Chief Executive  
Officer of the Hungarian Development Bank



**Dr Anett Pandurics**  
**Member of the Board of Directors**

Economist; Chair and Chief Executive  
Officer of Magyar Posta Insurance  
Company



**Bálint Szécsényi**  
**Member of the Board of Directors**

Economist; former Vice-Chairman of  
the Budapest Stock Exchange;  
Chairman and Chief Executive Officer  
of Equilor Investment Ltd.



**Balázs Szepesi**  
**Member of the Board of Directors**

Economist and sociologist;  
PhD in Political Science; Director of  
the MCC School of Economics and  
Entrepreneurship Lab




# Our Mission

„We are committed to improve health and quality of life globally as an independent company”

# Richter Group – Company Overview and Key Figures





Richter is a Hungary-based, innovation-driven specialty pharmaceutical company. Its strategy is built on organic growth complemented by targeted acquisitions, primarily in women's healthcare.

EUR 2.14 billion €

revenue

EUR 5.0 billion

market capitalisation



11,800

employees worldwide

(over 50% outside Hungary)





2,800

finished products



350

formulations



150

active substances



1,200

R&D professionals

9 original  
medicines

medicines

Nearly

10%

of revenue invested in R&D

Regional  
leader

R&D

**Our mission is to preserve health and improve quality of life by bringing to market high value-added original and biosimilar products in whose development and manufacture we possess specialised expertise.**

## Vertically Integrated Operation

Research and development

Pharmaceutical manufacturing

Wholesale and retail

Marketing



125

years of heritage  
(founded in 1901)



5

continents-spanning  
market network



100

countries

# Our Achievements



**Top 2**  
in the EU and Russian  
gynaecology market



**Market leader**  
in steroid manufacturing  
in the European Union



Among the world's  
**5 companies**  
that manufacture finished  
products from their own steroid  
active ingredients



**Blockbuster**  
product in the US



Our leading formulation is  
among the world's

**TOP 100**  
pharmaceutical products  
by sales



**Sustainability**  
at the core of our operations



Unique  
**biotechnology**  
capacities in Central  
and Eastern Europe



**ABBVIE**  
strategic partnership

# Our Awards – 2025



## GÁBOR ORBÁN

- Most Inspiring Leader of the Year Award (PwC)
- Officer's Cross of the Hungarian Order of Merit
- Mór Wahrmann Medal
- Manager of the Year Award
- "For a Healthy Life" Award (MOMOT)

## Best of Budapest Stock Exchange Awards

- Our Company ranked second among the highest-turnover share issuers of 2024.

## Prof. Dr E. Sylvester Vizi

- Jedlik Ányos Award

## TáRsalGó conversation card game

- HRKOMM Award – Gold
- Open Minded Companies Award – Category Winner

## Richter Centre

- Office of the Year Competition – Headquarters of the Year Award

## Innovative Company of the Year

- Figyelő TOP200 Award

## Bogsch Erik

- István Orbán Memorial Medal (MAGYOSZ)

## Most Attractive Employer

- 1st Place in the Pharmaceutical Industry Category, 2025 (PwC)

## Dr István Greiner

- Gábor Dénes Award

## Week of Openness

- Open Minded Companies Award – Special Mention

## RinGO – Internal communication platform

- HRKOMM Award - Silver

# Key Events – 2025



● Richter announces positive clinical trial results for the **RGB-19 biosimilar tocilizumab**.

● The **European Medicines Agency (EMA)** has accepted the marketing authorisation application submitted by Gedeon Richter Plc for its **RoActemra® biosimilar tocilizumab** product candidate (development code: RGB-19).

● **Richter and Adalvo** sign a joint development agreement for a semaglutide injection.

● **Richter** strengthens its cooperation with **Granata Bio** in the field of fertility treatment.

● **State Secretary** visits the Dorog site.

● The **Governor of Guangdong Province, China**, visits Richter.

● Richter has received approval from the European Commission for **Junod® and Yaxwer®**, indicated for the treatment of bone diseases and osteoporosis.

● It has been exactly **ten years** since Richter's original product, **cariprazine**, received approval from the U.S. Food and Drug Administration (FDA).

● The **FDA approved** two of Richter's denosumab biosimilar products.

● Richter's original product, **cariprazine**, has been present on the U.S. market for ten years, and **AbbVie** is planning a **13%** increase in sales by **2026**.

January

February

March

April

May

June

July

August

September

October

November

December

● The Committee for Medicinal Products for Human Use (**CHMP**) of the European Medicines Agency (**EMA**) issued a positive opinion recommending the granting of European marketing authorisation for **Junod® and Yaxwer®**, Richter's biosimilar denosumab products, for all indications of the reference medicines **Prolia®** and **Xgeva®** (Amgen).

● Richter takes part in the dialogue on the transformation of the global trading system affecting the **European pharmaceutical industry**.

● The **European Commission** has approved **Bio-Thera's BAT2206** (USYMRO®, a biosimilar ustekinumab).

● **Richter** successfully completed a multi-scope FDA inspection.

# Hungary-based International Corporate Group



Romania,  
Târgu Mureș  
600 employees



Poland,  
Mazowieckie  
826 employees




Germany,  
Bovenau  
376 employees



Russia,  
Yegoryevsk  
465 employees



India,  
Gujarat  
383 employees



- RG's global presence
- Manufacturing sites

50

Direct presence  
in 50 countries

93%

A total of 93% of revenue  
is generated abroad.

50%

More than 50% of employees  
work outside Hungary



Debrecen





Budapest



Dorog

## Distribution of Pharmaceutical Manufacturing Revenue by Region



124 years of heritage

100 countries across five continents

# Social Responsibility

## Foundation-based Programmes



## Corporate Brand Building for Professional Communities



In line with its mission of promoting health and improving quality of life, Richter supports and organises numerous healthcare, scientific and educational initiatives through foundations and grants.

## Brand Building / Education / CSR



## Employer Branding Programmes



# Business Units


Neuropsychiatry

Biotechnology



General Medicines Women's Healthcare

## Distribution of Pharmaceutical Manufacturing Revenue by Strategic Pillars



# Biotechnology



Richter's expertise continues to strengthen its presence in the rapidly growing segment of the biosimilars market. The Company develops and manufactures biological therapies in a field protected by high barriers of entry, offering innovative treatment options in rheumatology, autoimmune diseases and osteoporosis indications in Europe and Australia. Richter also provides development and manufacturing capacity to international partners under CDMO arrangements. In 2025, Richter received FDA approval for its biosimilar products for the first time, the denosumab products will be marketed in the United States by Hikma.

# Women's Healthcare



We are targeting women's health on a global scale, where we aim to play a leading role in the areas of uterine fibroids/endometriosis, contraception, vaginal infections, menopause and we are planning to introduce new therapies for the urinary tract, PCOS and women's oncology. Our focus on unmet medical needs, together with our leading role in innovation, supports the objective for the WHC business unit to become Europe's leading pharmaceutical manufacturer by the end of the decade, while delivering outstanding profitability.



# Neuropsychiatry




Building on our world-class early phase research capability in the central nervous system, we are building a robust development portfolio of small molecule drug candidates in indications where there is significant unmet medical need. We are working to continue to maximise the potential of cariprazine and are also developing our own original R&D projects.

# General Medicines



The activities of this segment are focused on a clearly defined geographical area; accordingly, the Central and Eastern European market accounts for more than 90% of the business unit's revenues. Our objective is to maintain the Company's prominent position in Hungary and to become a leading generic supplier in the Central and Eastern European markets. In addition to the treatment of central nervous system (generic) and cardiometabolic diseases, the business unit has set the goal of building a strong retail portfolio in the over-the-counter (OTC) medicines market through organic growth and acquisitions.

# Richter Strategy 2035



- We improve quality of life **globally** with a special focus on women and mental health patients
- We concentrate on the **development, manufacturing** and **commercialization** of pharmaceuticals
- Our **innovative** solutions elevate therapeutic standards while **affordable** medicines broaden patient access
- We aim to grow the non-royalty business to **twice the current size** and add royalties by the 2030's
- **Scalable solutions** will help us remain cost-efficient and limit adverse effects on the planet
- **Diverse and inclusive** teams

# Innovative Therapeutic Area

Our objective is to become global thought leaders by building an outstanding portfolio of leading therapies.

## GYNAECOLOGY

Through the development of market-leading solutions, our aim is to address unmet medical needs within our existing therapeutic areas, while also introducing new therapies in emerging strategic segments.

-  Contraception
-  Endometriosis
-  Menopause
-  Fertility
-  Urinary tract disorders
-  PCOS
-  Gynaecological oncology

## CNS

Our objective is to bring new blockbuster molecules to market in the field of neuropsychiatry following the expiry of the cariprazine patent, thereby strengthening our role as a global thought leader in the segment.

 Neuropsychiatry

 USA, Europe, Japan



# Affordable Therapeutic Area

Our aim is to offer widely accessible, affordable products, promoting equitable access and supporting general healthcare.



## BIOTECH

Our aim is to ensure affordable, high-quality products by building on our stable pipeline, while expanding our capabilities through our CDMO business.



Musculoskeletal system



Immunology



## GENMED

Our objective is to strengthen and extend generic operational excellence into Western Europe by leveraging business unit synergies within the Affordable pillar.



Cardiovascular system



Traditional CNS



Diabetes and pathological obesity



Blood therapies



USA, Europe, Japan



Europe

# Key Events of the Year

January February  
March April  
May June  
July  
August September  
October November  
December



# January



## **Richter Supports the Work of the Hungarian Interchurch Aid**

In January 2025, Gedeon Richter Plc supported the Hungarian Interchurch Aid with a monetary donation of HUF 15 million. The organisation has been a key player in domestic social and humanitarian assistance for decades.

For the Company, it is of particular importance to support organisations that demonstrably provide effective and transparent assistance to those in need. Through this contribution, Richter further reinforces its commitment to social responsibility and to supporting communities.

## **Richter: Positive Results from Clinical Trials of the RGB-19 Biosimilar Tocilizumab**

Gedeon Richter Plc announced that the Phase I and Phase III clinical trials of its biosimilar tocilizumab candidate, developed under the code RGB-19, have been successfully completed. The objective of the Phase I study was to demonstrate the pharmacokinetic equivalence of RGB-19 and the reference product RoActemra® in healthy adult male subjects. The Phase III study was a multicentre efficacy and safety trial conducted in patients with rheumatoid arthritis. Both studies met their primary endpoints, confirming clinical similarity to the reference product.

RGB-19 is a joint development of Richter and Mochida Pharmaceutical Co., Ltd., with the clinical trials conducted in Japan.

According to Dr Erik Bogsch, Head of Richter's Biotechnology Business Unit, the results demonstrate the strength of the Company's biotechnology platform and, following approval, will further expand the range of affordable medicines. Taiji Hayano, Executive Director of Mochida and Head of the Clinical Research and Development Division, added that the launch of RGB-19 could improve the quality of life of patients suffering from rheumatoid arthritis and other diseases.

# February

## Richter's Recognitions at the Best of Budapest Stock Exchange Awards

The Budapest Stock Exchange recognised outstanding performances on the Budapest trading floor in 2024 at the Best of Budapest Stock Exchange awards ceremony. On 13 February, the professional jury presented awards across 25 categories. Gedeon Richter Plc received two awards at the event.

Our Company ranked second among the highest-turnover share issuers of 2024. First place was awarded to OTP Bank Plc, while MOL Plc finished third. In addition to this recognition, Richter also received the award for Responsibility, Sustainability and Responsible Corporate Governance.





## Gábor Orbán Receives the Most Inspiring Leader of the Year Award

Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc, has received the Most Inspiring Leader of the Year Award, based on the results of the 14th PwC Hungary CEO Survey conducted by PwC Hungary. The survey, which was conducted between October and December 2024, found Gábor Orbán to be the most inspiring Hungarian CEO, based on the opinions of 265 company leaders. With this award, PwC Hungary recognises leaders who not only stand out for their business achievements but also set an example in the areas of organisational culture development, sustainable growth, and inspiring leadership.

*“For me, leadership is not just about business decisions, but also about inspiring others, creating growth opportunities, and building sustainable value. To me, this award is a testament to the fact that together at Richter we create value that go beyond business success,”* said Gábor Orbán.

The award was presented by László Radványi, Chief Executive Officer of PwC Hungary, at PwC’s Budapest headquarters.

## HUF 100 Million Grant to Support Science Education Development in Public Schools

The Gedeon Richter Plc Centenary Foundation has announced the second round of its infrastructure development grant programme for public education institutions, with a total funding allocation of HUF 100 million. The aim of the programme is to improve the conditions for science education and to support the creation of modern learning environments.

The call for applications enables schools to procure laboratory and demonstration equipment, scientific instruments, specialised classroom furnishings, furniture and storage solutions that enhance the teaching of biology, chemistry and physics. The grant does not cover construction works or consumable materials.

In the previous year, 35 schools received funding, which enabled them to modernise their laboratories, storerooms and specialised classrooms. These developments have made a tangible contribution to raising the standard of science education.

*“This support scheme not only provides an opportunity for applicant schools to expand the resources available for science education, but also represents a commitment on the part of Richter to offer teachers and students engaging and instructive insights into the fascinating world of modern pharmaceutical research through study visits and other forums,”* said Prof. Dr Csaba Szántay, Scientific Chief Advisor of Richter and Head of Healthcare and Education Support.

”

# March



## **Prof. Dr E. Sylvester Vizi Honoured with the Jedlik Ányos Award**

In 2025, the Hungarian Intellectual Property Office awarded the Jedlik Ányos Award to E. Sylvester Vizi, Chairman of the Board of Directors of Gedeon Richter Plc. The award recognises outstanding inventive activity and achievements in the field of industrial property protection.

Prof. Dr E. Sylvester Vizi is a physician, pharmacologist and academician, and served as President of the Hungarian Academy of Sciences between 2002 and 2008. His scientific work focuses on the study of neuronal signal transmission, which is of fundamental importance in the treatment of neurological diseases and in drug development. His research has resulted in numerous international patents; over the course of his career, he has contributed a total of 39 patents to the advancement of medical science and the pharmaceutical industry, opening new horizons in both scientific understanding and therapeutic innovation.

He has been a member of the Board of Directors of Gedeon Richter Plc since 2008, and has served as Chairman since 1 March 2024. Under his leadership, the Company continues to strengthen its innovation activities and industrial property strategy, contributing to the preservation of its international competitiveness.

## Gábor Orbán Awarded the Officer's Cross of the Order of Merit of Hungary

Gábor Orbán, economist, Chief Executive Officer of Gedeon Richter Plc, President of the National Foundation for Healthcare and Medical Education, and member of the National Science Policy Council and the Stock Exchange Advisory Board of the Budapest Stock Exchange Plc, received the Officer's Cross of the Order of Merit of Hungary.

The decoration was presented by Csaba Lantos, Minister of Energy, and Natália Borsos-Papp, Deputy State Secretary for Strategy at the Ministry of Energy, at the Pesti Vigadó during the state awards ceremony held in connection with the national holiday.

The award recognises Gábor Orbán's decades-long professional contribution to the development of the Hungarian economy and the healthcare industry, as well as his roles in the scientific and financial sectors. His career is characterised by consistent, long-term thinking and a strong commitment to sustainable growth.

His leadership has contributed to Richter's evolution into an internationally recognised, innovation-driven Hungarian pharmaceutical company.





RICHTER ANNA DÍJ  
*Szívügyünk a fejlődés*

## Richter Anna Awards Presented for the Seventh Time

In 2025, the Richter Anna Awards were presented for the seventh time. At the formal awards ceremony held on 19 March, six teams received awards—five selected by the jury and one audience award winner. Established by Gedeon Richter Plc in 2019, the initiative supports women-led teams implementing innovative projects that address unmet needs in the fields of education, healthcare, pharmacy and research.

Applications are open to teams of up to five members from institutions, organisations or professional communities across five categories: physician, healthcare professional, educator, pharmacist/researcher and junior. Each winning team received HUF 4 million to support the implementation of their project, while the audience award was granted to the team receiving the highest number of votes.

”

*“The applications themselves demonstrate the need to support creative teams working in healthcare, education and pharmacy. I am proud that, through the Richter Anna Award, we are able to support them for the seventh time,”* said Zsuzsa Beke, Head of Global Public Relations, CSR and Public Affairs at Gedeon Richter Plc.

## Another Milestone in Biosimilar Development

The European Medicines Agency (EMA) has accepted Richter's marketing authorisation application for its proposed biosimilar to RoActemra® tocilizumab (development code: RGB-19). This step represents a further milestone in Richter's biosimilar development programme.

Tocilizumab, the first biologic to inhibit IL-6 signaling, is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis, cytokine release syndrome and COVID-19. Richter submitted a comprehensive analytical and clinical data package, which comprises data from a Phase I pharmacokinetic/pharmacodynamic (PK/PD) similarity study in healthy male volunteers and a multicenter efficacy and safety comparability Phase III study in patients with rheumatoid arthritis. According to the data package, RGB-19 demonstrated equivalent efficacy, safety and immunogenicity to the reference product, RoActemra.

*“The submission of the tocilizumab biosimilar to the EMA is yet another milestone in building Richter's affordable medicines portfolio. This biosimilar – when approved – will provide access to a broad range of our patients in Europe to this important biological drug”* said Dr. Erik Bogsch, Head of the Biotechnology Business Unit.

”

# April



## Richter Merit Medal Award Gala

Established in 2022, the Richter Merit Medal Award not only recognises the work of physicians and pharmacists but also supports the wider dissemination of innovative ideas and best practices. The award honours general practitioners, specialist physicians and pharmacists in the categories of patient communication, prevention, and scientific and innovative activity.

Winning applications receive a prize of HUF 2 million, while special award recipients are granted HUF 500,000.

In April, the Richter Merit Medal Award in the specialist physician category was presented for the third time, through which the Company expresses its appreciation to those doctors who, through their professional expertise, humanity and innovative approach, help shape the future of Hungarian healthcare. The award ceremonies for the pharmacist and general practitioner categories will be held in November.

*“The Richter Merit Medal plays an important role in recognising the medical profession,”* said Zsuzsa Beke, Head of Global Public Relations, CSR and Public Affairs at Gedeon Richter Plc.

To date, a total of 24 specialist physicians have received the award, with total prize funding exceeding HUF 25.5 million.

## Richter's Two Biosimilar Denosumab Products Receive Positive CHMP Opinion

Gedeon Richter Plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company's biosimilar denosumab products, Junod® and Yaxwer®. The Committee recommends granting European marketing authorisation for these products for all indications of the reference medicines Prolia® and Xgeva® (Amgen).

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone and treating unresectable giant cell tumour of the bone.

*“The positive CHMP opinion for Junod® and Yaxwer® paves the way for EU marketing authorisation of these vital medicines, marking Richter's first monoclonal antibody biosimilar approval,”* said Erik Bogsch, Head of the Biotechnology Business Unit at Gedeon Richter Plc.

He added: *“The two new products enhance our bone health portfolio, joining Terrosa®, which is already on the market.”*



# May

## **Richter and Adalvo Sign Co-Development Agreement for a Semaglutide Injection**

Gedeon Richter Plc and Adalvo Ltd have entered into a strategic co-development and license agreement for a proposed bioequivalent to semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. The collaboration aims to provide broader global access to high-quality, affordable therapies for the treatment of obesity.

The agreement covers global rights, with both companies sharing development costs and net profits across each other's markets, while Richter is entitled to use the CMO supply chain selected within the framework of the agreement to manufacture the product and, subject to certain conditions, also reserves the right to manufacture it in its own facilities for direct commercialization.

”

*“We are pleased to announce this new strategic partnership with Adalvo. We believe that together we can build a global reach to serve patients living with obesity worldwide,”* said Bence Kovács, Global Head of the General Medicines at Gedeon Richter Plc.

## Richter's CEO Awarded the Wahrmann Mór Medal

At the 199th ceremonial General Assembly of the Hungarian Academy of Sciences, one of the most prestigious Hungarian distinctions in the scientific community—the Wahrmann Mór Medal—was presented to Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc. The award is granted in recognition of contributions to the advancement of science, support for research and development, and professional achievements that serve the public good.

The distinction derives its particular significance from its history: the Academy has conferred the medal since 1897, and past recipients include figures of historic importance such as András Mechwart, a pioneer of Hungary's electrical industry, and Pál Bezerédj, a leading figure in Hungarian silk production. To this day, the medal is awarded to individuals whose work creates lasting value for the country's intellectual and economic development.

As the head of an innovation-driven Hungarian pharmaceutical company with more than 120 years of history, Gábor Orbán has earned the recognition of the professional community by promoting collaboration between research institutions and industry, supporting the development of university education and research, and consistently advocating the importance of basic research.

Gábor Orbán has led Gedeon Richter Plc since November 2017. He joined the Company in 2016 as Director of Corporate Strategy, subsequently serving as Deputy Chief Executive Officer and later as a member of the Board of Directors.

The award also represents an affirmation for Richter: the integration of scientific excellence, industrial innovation and social responsibility creates long-term value and contributes to strengthening Hungary's international standing.

## The “Gedeon Richter House of Hope” Opens Its Doors in Bamako

With the financial support of Gedeon Richter Plc, the Gedeon Richter House of Hope has opened in Bamako, the capital of Mali. The centre provides healthcare, educational and social assistance to vulnerable women, aiming to support 300 women each year. Richter has made a long-term commitment to ensuring the continued operation of the centre.

Operational since early 2025, the House of Hope offers medical, psychological and legal support, as well as employment opportunities, to women escaping violence. The project was implemented in cooperation with the Close to Africa Foundation, the Sini Sanuman Foundation, and the Hungary Helps Programme. The building was designed by a team of young Hungarian architects.

*“We will continue to support women in need across Africa with the same dedication and passion that have already driven our successful initiatives in many of our markets,”* said Zsuzsa Beke, Head of Global Public Relations, CSR and Public Affairs at Richter.

*“I am confident that through this initiative we can give 300 women a second chance every year,”* added Andrea Morris, President of the Close to Africa Foundation.



## Richter Acquires a Stake in Granata Bio, Strengthening Collaboration in Fertility Treatment

Gedeon Richter Plc announced that it has acquired a significant equity stake in Granata Bio, a U.S.-based biotechnology company specialising in reproductive health. Through the transaction, Richter becomes one of Granata Bio's key investors and secures a seat on the company's Board of Directors.

Granata Bio's expertise in business development, research and development, regulatory strategy and commercialisation makes it an ideal partner. The partnership aligns with Richter's objective to strengthen its Women's Health Care (WHC) business unit and to expand its presence in the United States.

The collaboration includes the joint development of Bemfola, Richter's recombinant FSH product, for the U.S. market, as well as Granata Bio's royalty purchase agreement for hMG, which will provide Richter with future royalty income.

The follitropin market generated revenues of EUR 2.3 billion in 2024, with annual growth of 11%, representing a significant opportunity for Richter.

*“These transactions demonstrate our commitment to the U.S. market. Our collaboration with Granata Bio will significantly support our ambitions in this important region,”* said Péter Turek, Global Head of the WHC Business Unit at Gedeon Richter Plc.



## Governor of Guangdong Province Visits Richter

On 15 May, Gedeon Richter Plc welcomed Wang Weizhong, Governor of Guangdong Province, to its Budapest headquarters. The Governor arrived in Hungary with a high-level governmental and business delegation. The meeting was attended on the Chinese side by government and Party officials as well as business representatives, and on the Richter side by Gábor Orbán, Chief Executive Officer; Prof. Dr E. Sylvester Vizi, Chairman of the Board of Directors; Tamás Szolyák, Commercial Director; and András László Kovács, Chief Financial Officer.

During the meeting, the Chinese delegation highlighted the growing demand in China for high-quality, affordable medicines and expressed appreciation for Richter's role in European pharmaceutical research and development.

Gábor Orbán emphasised that Richter is open to mutually beneficial, equal partnerships in which both parties actively contribute to value creation in research and development. He underlined that high-level meetings of this kind play a key role in building trust and fostering long-term cooperation.

The parties agreed that the visit provides a solid foundation for continued economic and professional dialogue between Guangdong Province and Richter in the future.



## Gábor Orbán Awarded Manager of the Year

At the Managers' Association's jubilee 30th Manager of the Year Awards Gala, Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc, received the 2024 Manager of the Year Award. One of the most prestigious honours in Hungarian business life was presented by István Kapitány, President of the Managers' Association, at the Hungarian State Opera House in front of approximately 450 invited guests.

Each year, the award recognises leaders who, alongside their business achievements, set an example as values-driven, credible and socially responsible executives.

Gábor Orbán has led Gedeon Richter since 2017. Under his leadership, the more than 120-year-old company has entered a new growth trajectory, marked by strategic acquisitions, the launch of new business units, and a multi-year R&D collaboration with a major American company.

Through the Manager of the Year Award, the Managers' Association recognises responsible and inspiring leaders whose work contributes to the development of the Hungarian economy.



*“This recognition also belongs to my mentors, my family and the fantastic team—without them, this would not have been possible. It gives me strength and momentum for the work ahead,”* said Gábor Orbán.



# June



## The Semmelweis–Richter Journalism Award Recognises European Excellence in Health Journalism

The Semmelweis–Richter Journalism Award was presented for the first time, recognising outstanding European representatives of health journalism. The award was established by Semmelweis University with the support of Gedeon Richter Plc, to honour journalists whose work contributes to the credible communication of health-related knowledge and to strengthening public dialogue.

The award was announced in two categories—women’s health and pharmaceutical innovation—and attracted more than 70 submissions from over twenty European countries.

At the awards ceremony, Dr Béla Merkely, Rector of Semmelweis University, and Gábor Orbán, Chief Executive Officer of Richter, emphasised that credible, science-based journalism is essential to building trust and enhancing society’s health awareness.

Award recipients included Grace Browne (WIRED, UK), Tom Whipple (The Times), Shauna Bowers (The Irish Times), as well as journalists from Süddeutsche Zeitung, swissinfo.ch, and the Italian magazine Focus.

The aim of the award is to promote international standards of health education and responsible public information.

# July

## **European Commission Approves Richter's Biosimilar Products Junod<sup>®</sup> and Yaxwer<sup>®</sup>**

Gedeon Richter Plc announced that the European Commission has granted marketing authorisation for the Company's biosimilar denosumab products Junod<sup>®</sup> and Yaxwer<sup>®</sup>. The decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and represents a significant milestone for Richter, as it marks the Company's first approval of a biosimilar monoclonal antibody.

Junod<sup>®</sup> and Yaxwer<sup>®</sup> have been authorised for all indications of the reference medicines Prolia<sup>®</sup> and Xgeva<sup>®</sup> (Amgen). Accordingly, they are indicated, among others, for the treatment of osteoporosis in postmenopausal women, for the prevention of skeletal-related events caused by bone metastases from solid tumors, and for the treatment of unresectable giant cell tumour of bone.

The approval is the result of a comprehensive development programme demonstrating biosimilarity to the reference products in terms of quality, safety and efficacy.

# August

## **European Commission Approves Bio-Thera's BAT2206 (USYMRO<sup>®</sup>, a Biosimilar Ustekinumab)**

Gedeon Richter Plc announced that the European Commission has granted marketing authorisation for BAT2206 (ustekinumab), a biosimilar to Stelara<sup>®</sup>, developed by Bio-Thera Solutions Inc. ("Bio-Thera"). The decision follows the positive opinion issued on 19 June 2025 by the Committee for Medicinal Products for Human Use (CHMP). Richter will market the product in Europe under the brand name USYMRO<sup>®</sup>.

*"We are pleased that Richter will further strengthen patient access to biosimilars in Europe through bringing USYMRO<sup>®</sup> to market. As a result of Bio-Thera's success in gaining EC approval, Richter is expanding its biosimilar portfolio subsequent to the recent EC approvals of its in-house developed denosumab biosimilars,"* said Dr. Erik Bogsch, Head of the Biotechnology Business Unit at Richter.

Bio-Thera and Richter entered into a licence and commercialization agreement for USYMRO<sup>®</sup> (BAT2206) in October 2024. Under the terms of the agreement, Bio-Thera is responsible for the development and manufacturing of the product, and Richter obtained exclusive rights to commercialize it in the EU, the United Kingdom, Switzerland, and selected other countries.

# September

## **Richter's Original Product Cariprazine Received FDA Approval Exactly Ten Years Ago**

Ten years ago, Gedeon Richter Plc's original antipsychotic medicine, cariprazine, received approval from the U.S. Food and Drug Administration (FDA). Cariprazine was the first medicine developed in Hungary to be launched on the U.S. market. The research project, initiated in 1999, was carried out in cooperation with Forest Laboratories (now AbbVie) and has since become one of the most significant innovation successes in the history of the Hungarian pharmaceutical industry.

Cariprazine was first synthesised in 2002, entered clinical trials in 2004, received FDA approval in 2015, and was subsequently authorised by the European Medicines Agency (EMA) in 2017. Since then, its range of indications has expanded to include the treatment of bipolar depression and adjunctive therapy for major depressive disorder.

The medicine is now available in nearly 70 countries, providing treatment to more than 2 million patients. It achieved blockbuster status by 2020, and by 2024 its annual sales exceeded USD 3 billion.

*"The development of cariprazine exemplifies the very best of Hungarian scientific ingenuity and international collaboration,"* said Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc.

## Hungarians Place Their Trust in Smart Cities and Personalised Medicines – BoschxRichter Research on the Innovations of the Future

According to a joint nationwide survey conducted in Hungary by the Bosch Group and Gedeon Richter Plc, the majority of Hungarians expect innovation to improve their quality of life. The survey entitled “Innovation Top List: The Innovations Hungarians Believe In” was carried out on behalf of the two companies by Europion, based on responses from more than 1,000 participants. The findings were presented in Budapest at the BoschxRichter Innovators’ Day.

Respondents anticipate the most significant breakthroughs in the fields of sustainable energy (81%), climate protection (80%), and healthcare and biotechnology (77%). In terms of mobility, the automotive industry is considered the most innovative sector (48%). Within the next decade, respondents expect the widespread adoption of electromobility, the emergence of smart cities, and the renewal of public transport.

With regard to pharmaceutical developments, the public primarily expects progress in the treatment of currently incurable diseases (60%), the reduction of side effects (51%), and the introduction of new, personalised medicines (32%). At the same time, there is strong scepticism towards mRNA technologies, while interest in gene editing and 3D-printed organs is on the rise.




## FDA Approves Our Two Denosumab Biosimilar Products

Gedeon Richter Plc and Hikma Pharmaceuticals Plc announced that the U.S. Food and Drug Administration (FDA) has approved their two denosumab biosimilar products, Enoby™ and Xtrenbo™, referencing Prolia® and Xgeva® respectively. The FDA approval was granted on the basis of a comprehensive analytical, non-clinical and clinical development programme that demonstrated the products' equivalence to the reference medicines in terms of quality, efficacy and safety.

Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer that has spread to the bone, and treating unresectable giant cell tumour of the bone.

Richter and Hikma entered into a license and commercialization agreement for RGB-14 products in December 2021, under which Richter is responsible for development and manufacturing, while Hikma is responsible for FDA registration and commercialisation in the U.S..

Enoby™ and Xtrenbo™ are the first FDA-approved biosimilar products in Richter's history, reinforcing the Company's position in the global biotechnology sector.



# October

## **Richter Successfully Completes Comprehensive FDA Inspection**

Gedeon Richter Plc has successfully completed a multi-scope inspection conducted by the U.S. Food and Drug Administration (FDA), as a result of which the Company received approval for its biosimilar products for the first time. The successful inspection confirms that Richter's development, manufacturing and quality assurance systems meet the requirements of one of the world's most stringent regulatory authorities.

The FDA carried out nine on-site inspections—at five clinical sites, three supporting laboratories and the biotechnology facility in Debrecen—where active pharmaceutical ingredient manufacturing, sterile finished product operations and development processes were assessed. As a result, Richter has become one of the few sterile and biotechnology manufacturers in Central and Eastern Europe to hold FDA approval.

”

*“I am proud of the team, who worked in perfect coordination to deliver high-quality, affordable biological therapies to patients worldwide,”* said Dr. Erik Bogesch, Head of Richter's Biotechnology Business Unit.

## 14,000 Health Screenings and a Record Donation at Richter Health Cities in 2025

More than 14,000 health screenings, several thousand visitors and a total of HUF 116,322,500 in donations marked the conclusion of Gedeon Richter Plc's nationwide health promotion programme, Richter Health Cities, in 2025. The six-stop series visited Sátoraljaújhely, Győr, Gyöngyös, Dunaújváros, Sáropatak and Tatabánya.

During the programme, participants were able to take part in free screenings, lectures and counselling sessions. Through their participation, visitors could add donation points worth HUF 500 each to Richter's HUF 3.5 million base donation. The highest level of support was raised in Gyöngyös, where a record HUF 29,068,000 was donated, while the event in Sáropatak concluded with HUF 24.9 million in contributions.

For 16 years, the programme has continuously supported the health preservation of the Hungarian population. To date, more than 251,000 screenings have been carried out at 113 events, and a total of HUF 834 million has been donated to Hungarian healthcare institutions.

Richter Health Cities will continue next year, reaching even more communities to further strengthen prevention, health awareness and self-care.



# November

## **Richter Receives Figyelő TOP200 Award**

Gedeon Richter Plc received the “Innovative Company of the Year” award at one of the most prestigious events in Hungarian business life, the Figyelő TOP200 Gala. The professional jury recognised the Company’s outstanding research and development and innovation performance, further strengthening its position at the forefront of the Hungarian and international pharmaceutical industry.

The award was accepted by András László Kovács, Deputy Chief Executive Officer and Chief Financial Officer of Richter.

This recognition not only confirms our commitment to continuous renewal, but also represents a shared success reflecting the work of all our colleagues.

Figyelő TOP200 is a publication ranking Hungary’s largest companies and has been recognising outstanding domestic companies and business leaders for 26 years. The awards were once again presented by the professional jury at this year’s Figyelő TOP200 Gala.

## Erik Bogsch Receives the István Orbán Memorial Medal from MAGYOSZ

The Association of Hungarian Pharmaceutical Manufacturers (MAGYOSZ) has awarded the István Orbán Memorial Medal to Erik Bogsch, Lifetime Honorary Chairman of Gedeon Richter Plc.

The memorial medal, named after MAGYOSZ's founding president, was established to recognise individuals whose activities have made an outstanding and decisive contribution to the domestic and international recognition, reputation and strengthening of the Hungarian pharmaceutical industry.

Mr Bogsch has played a defining role in the life of Richter and the Hungarian pharmaceutical sector for more than 30 years. His name is closely associated with the Company's strategic renewal, stock exchange listing and international expansion. Between 2006 and 2016, he also served as President of MAGYOSZ.

At MAGYOSZ's annual general meeting held on 15 May 2025, Zsuzsa Beke, Head of Global PR, CSR and Government Relations at Richter, was elected to the Board to succeed the outgoing board member, Erik Bogsch.





# TABUTÉMÁK

## A NŐI EGÉSZSÉGBEN

### **Taboos and Social Pressure – Richter’s International Research on Women’s Health**

Gedeon Richter Plc conducted a study involving a total of 12,000 women across six European countries—Hungary, Germany, Italy, Portugal, Spain and the United Kingdom—examining the impact of taboos surrounding women’s health. The findings indicate that a large proportion of women experience symptoms and pain—related to sexuality, fertility and menopause—that significantly affect their daily lives, yet many choose not to speak about them, seek help late, or do not visit a healthcare professional at all.

Women’s health is one of Richter’s key business areas, underpinned by more than a century of professional commitment. The Company’s objective is to provide women with real, reliable solutions and credible information, while emphasising that these topics deserve a place in public and societal dialogue.

# December

## **2025 Rátz Tanár Úr Lifetime Achievement Award Presented**

The Rátz Tanár Úr Lifetime Achievement Award was presented for the 25th time in 2025 at the headquarters of the Hungarian Academy of Sciences. The award was established in 2000 by the Foundation for Hungarian Science Education, with the support of Ericsson Hungary, Graphisoft SE and Gedeon Richter Plc.

In the jubilee year, eight teachers received the award in the fields of mathematics, physics, chemistry and biology, each receiving a prize of HUF 2.5 million. The award recognises outstanding teaching careers dedicated to talent development and the advancement of science education. Over the past 25 years, nearly 200 educators have been honoured.





GEDeon RICHTER

1103 Budapest, Gyömrői út 19–21.

Telephone: +36 1 431 4000

[www.gedeonrichter.com](http://www.gedeonrichter.com)